BRPI0406796A - Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina - Google Patents

Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina

Info

Publication number
BRPI0406796A
BRPI0406796A BR0406796-7A BRPI0406796A BRPI0406796A BR PI0406796 A BRPI0406796 A BR PI0406796A BR PI0406796 A BRPI0406796 A BR PI0406796A BR PI0406796 A BRPI0406796 A BR PI0406796A
Authority
BR
Brazil
Prior art keywords
lonidamine
reducing
prophylaxis
bhp
pharmaceutical composition
Prior art date
Application number
BR0406796-7A
Other languages
English (en)
Inventor
George Tidmarsh
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of BRPI0406796A publication Critical patent/BRPI0406796A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

"MéTODOS PARA TRATAR HIPERTROFIA PROSTáTICA BENIGNA, PARA REDUZIR UM SINTOMA ASSOCIADO COM A MESMA, PARA REDUZIR O TAMANHO DA PRóSTATA EM UM INDIVìDUO HUMANO E PARA PROFILAXIA DE BHP, COMPOSIçãO FARMACêUTICA ORAL DE DOSE UNITáRIA, E, USO DE LONIDAMINA OU UM ANáLOGO DE LONIDAMINA". Método para tratamento ou profilaxia de hiperplasia prostática benigna por administração de lonidamina ou um análogo de lonidamina é provido. Também são providas as formas de dosagem unitária de lonidamina ou um análogo, utilizáveis para este tratamento e profilaxia.
BR0406796-7A 2003-01-17 2004-01-16 Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina BRPI0406796A (pt)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US44111003P 2003-01-17 2003-01-17
US44234403P 2003-01-23 2003-01-23
US45866503P 2003-03-28 2003-03-28
US45884603P 2003-03-28 2003-03-28
US45866303P 2003-03-28 2003-03-28
US46001203P 2003-04-02 2003-04-02
US47290703P 2003-05-22 2003-05-22
US48826503P 2003-07-18 2003-07-18
US49616303P 2003-08-18 2003-08-18
PCT/US2004/001141 WO2004064735A2 (en) 2003-01-17 2004-01-16 Treatment of benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
BRPI0406796A true BRPI0406796A (pt) 2006-01-17

Family

ID=32777423

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406796-7A BRPI0406796A (pt) 2003-01-17 2004-01-16 Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina

Country Status (13)

Country Link
US (4) US6989400B2 (pt)
EP (2) EP1592430A4 (pt)
JP (2) JP2006516571A (pt)
KR (2) KR20050098249A (pt)
AU (2) AU2004206870A1 (pt)
BR (1) BRPI0406796A (pt)
CA (2) CA2513575A1 (pt)
DE (1) DE04702967T1 (pt)
ES (1) ES2254046T1 (pt)
IL (1) IL169685A0 (pt)
MX (2) MXPA05007571A (pt)
NO (1) NO20053783L (pt)
WO (2) WO2004064735A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
US7524885B2 (en) * 2002-04-01 2009-04-28 The Governors Of The University Of Alberta Compounds that stimulate glucose utilization and methods of use
KR20050098249A (ko) 2003-01-17 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 양성 전립선 비대증의 치료방법
CN1972697A (zh) 2004-06-17 2007-05-30 威斯康星校友研究基地 治疗发作和发作性疾病的化合物和方法
WO2006091790A1 (en) 2005-02-23 2006-08-31 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
WO2007101148A2 (en) * 2006-02-24 2007-09-07 Board Of Regents, The University Of Texas System Hexose compounds to treat cancer
MX2008011127A (es) 2006-03-02 2008-10-31 Astellas Pharma Inc INHIBIDOR DE 17ß HSD TIPO 5.
EP2114413B1 (en) * 2006-12-18 2014-10-22 The Johns Hopkins University Therapeutics for treating cancer using 3-bromopyruvate
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
CA2694216A1 (en) 2007-07-24 2009-01-29 Astellas Pharma Inc. Benzimidazole derivative
CN101821253B (zh) 2007-08-31 2013-07-17 安斯泰来制药有限公司 哌啶衍生物
US8603123B2 (en) 2008-04-28 2013-12-10 Urotech, Inc. Benign prostatic hyperplasia surgical system featuring mechanical coring probe with live aspiration
US9492417B2 (en) * 2008-08-21 2016-11-15 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
PL2391363T3 (pl) * 2009-01-29 2017-03-31 Young Hee Ko Kompozycje i sposoby do leczenia raka
JPWO2013153821A1 (ja) * 2012-04-12 2015-12-17 学校法人北里研究所 Ｐｄｋ４阻害剤及びその利用
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
CN106102725A (zh) 2014-01-14 2016-11-09 约翰斯·霍普金斯大学 包封选择性atp抑制剂的环糊精组合物及其应用
EP3370712B1 (en) 2015-11-06 2025-02-19 The Johns Hopkins University 3-bromopyruvate for treating liver fibrosis
EP3564214B1 (en) 2018-05-04 2024-07-03 Universita' Degli Studi G. D'annunzio Chieti - Pescara Indazole derivatives as modulators of the cannabinoid system
CN116438162A (zh) * 2020-09-17 2023-07-14 伊赛恩特制药公司 Mas相关g蛋白受体x4的调节剂及相关产物和方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1052111B (it) 1972-02-29 1981-06-20 Acraf Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati
US4684627A (en) 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
CA1289077C (en) 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
US5260327A (en) * 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
AU1893492A (en) * 1991-04-17 1992-11-17 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
EP0831829B1 (en) 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
FR2737721B1 (fr) 1995-08-08 1997-09-05 Roussel Uclaf Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant
ATE202551T1 (de) 1995-10-18 2001-07-15 Kanoldt Arzneimittel Gmbh Lignane, verfahren zu ihrer herstellung, ihre pharmazeutische compositionen und anwendungen
DE19621319A1 (de) 1996-05-28 1997-12-04 Hoechst Ag Bis-ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6054432A (en) 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
IT1289938B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
IT1289939B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Composizione farmaceutica acquosa comprendente un principio attivo altamente insolubile in acqua
CN1078462C (zh) * 1997-07-09 2002-01-30 辛国芳 棉酚和/或其衍生物作为有效成分在制备用于治疗前列腺炎的栓剂中的应用
CA2331620A1 (en) * 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6001865A (en) * 1999-05-04 1999-12-14 Angelini Pharmaceuticals Inc. 3-substituted 1-benzyl-1H-indazole derivatives as antifertility agents
KR20050098249A (ko) 2003-01-17 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 양성 전립선 비대증의 치료방법
CN1960719B (zh) * 2004-03-25 2011-12-07 密执安州立大学董事会 棉酚共结晶及其应用

Also Published As

Publication number Publication date
EP1610778A4 (en) 2006-05-31
CA2513575A1 (en) 2004-08-05
DE04702967T1 (de) 2006-06-22
AU2004206870A1 (en) 2004-08-05
US20040167196A1 (en) 2004-08-26
US6989400B2 (en) 2006-01-24
NO20053783D0 (no) 2005-08-09
EP1592430A2 (en) 2005-11-09
WO2004064736A3 (en) 2005-05-06
WO2004064735A2 (en) 2004-08-05
JP2006516571A (ja) 2006-07-06
US20050271723A1 (en) 2005-12-08
IL169685A0 (en) 2007-07-04
CA2513572A1 (en) 2004-08-05
MXPA05007572A (es) 2005-11-17
WO2004064735A3 (en) 2004-12-16
KR20050098250A (ko) 2005-10-11
NO20053783L (no) 2005-09-27
EP1610778A2 (en) 2006-01-04
AU2004206869A1 (en) 2004-08-05
ES2254046T1 (es) 2006-06-16
EP1592430A4 (en) 2006-05-31
KR20050098249A (ko) 2005-10-11
MXPA05007571A (es) 2005-11-17
JP2006518343A (ja) 2006-08-10
US20050272795A1 (en) 2005-12-08
WO2004064736A2 (en) 2004-08-05
US20050272796A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
WO2004064734A3 (en) Combination therapies for the treatment of cancer
GT200900154A (es) Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BRPI0410306A (pt) métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
BRPI0408858A (pt) uso de um inibidor de ibat ou, um sal, solvato, solvato de um tal sal ou uma pró-droga destes, farmaceuticamente aceitáveis, composição farmacêutica, e, método de tratamento e/ou profilaxia de constipação em um animal de sangue quente
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
NO20053783L (no) Behandling av godartet prostatahyperplasi
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
BR0307410A (pt) Uso de inibidores de pde5 no tratamento da cicatrização e fibrose
BR0315593A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
BR0317095A (pt) Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]